Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,029.20INR
19 Jul 2018
Change (% chg)

Rs-36.45 (-1.76%)
Prev Close
Rs2,065.65
Open
Rs2,077.80
Day's High
Rs2,077.80
Day's Low
Rs2,025.00
Volume
762,721
Avg. Vol
790,557
52-wk High
Rs2,787.00
52-wk Low
Rs1,887.00

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): Rs394,104.81
Shares Outstanding(Mil.): 165.88
Dividend: 20.00
Yield (%): 0.84

Financials

  REDY.NS Industry Sector
P/E (TTM): 32.79 30.93 32.76
EPS (TTM): 72.46 -- --
ROI: -- 15.07 14.61
ROE: -- 16.60 16.34

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

16 Jul 2018

BUZZ-India's Dr.Reddy's Laboratories plunges; Indivior wins preliminary injunction against co

** Dr.Reddy's Laboratories Ltd falls as much as 10.8 pct to a five-week low of 2,069.95 rupees

16 Jul 2018

BUZZ-India's Dr.Reddy's rises on US drug hopes; UK rival Indivior cuts guidance

** Dr.Reddy's Laboratories Ltd rise as much as 3.8 pct to 2,387.65 rupees, its highest in 3 weeks

12 Jul 2018

Indivior says 2018 profit to fall short after U.S. market hit

British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.

11 Jul 2018

UPDATE 1-Indivior says 2018 profit to fall short after U.S. market hit

July 11 British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.

11 Jul 2018

BUZZ-Weak Q1 expected for Cadila, Lupin; improving trends for Cipla, Sun - Credit Suisse

** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)

09 Jul 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

UPDATE 2-Indivior gets breather after court extends order blocking generic rival

* Update on Sublocade will be key to sentiment-Jefferies (Adds share move, analyst comments)

29 Jun 2018

U.S. court extends Indivior's restraining order against Dr. Reddy's generic drug

June 29 British drugmaker Indivior Plc said on Friday a U.S. court extended the restraining order blocking Indian pharmaceutical firm Dr.Reddy's Laboratories from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

Earnings vs. Estimates